Allosteric modulators of NR2B‐containing NMDA receptors: molecular mechanisms and therapeutic potential

No abstract is available for this paper.

• Publication year

  2009

• Venue

  British Journal of Pharmacology

• Publication date

  2009-08-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1476-5381.2009.00304.xPMID 19594762PMCID PMC2765303
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Guide to Receptors and Channels (GRAC), 4th edition

  2009cited by this paper
• Structural Basis of NR2B-Selective Antagonist Recognition by N-Methyl-d-aspartate Receptors

  2009influential reference
• Zinc at glutamatergic synapses.

  2009influential reference
• In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death.

  2009cited by this paper
• Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N‐methyl‐d‐aspartate receptor

  2008influential reference
• Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia.

  2008cited by this paper
• Guide to Receptors and Channels (GRAC), 3rd edition

  2008cited by this paper
• Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

  2008cited by this paper
• Differential Roles of NMDA Receptor Subtypes in Ischemic Neuronal Cell Death and Ischemic Tolerance

  2008cited by this paper
• The Activation Gate and Gating Mechanism of the NMDA Receptor

  2008cited by this paper
• An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

  2008cited by this paper
• Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.

  2008cited by this paper
• Presynaptic glutamate receptors: physiological functions and mechanisms of action

  2008cited by this paper
• Structural Basis of NR 2 B-Selective Antagonist Recognition by N-Methyl-D-aspartate Receptors

  2008influential reference
• Glycine transport inhibitors and the treatment of schizophrenia.

  2008cited by this paper
• Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies

  2008cited by this paper
• Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition.

  2008influential reference
• Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks.

  2008cited by this paper
• NMDA Receptor Subunits Have Differential Roles in Mediating Excitotoxic Neuronal Death Both In Vitro and In Vivo

  2007cited by this paper
• Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors.

  2007cited by this paper
• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

  2007cited by this paper
• Improving solubility of NR2B amino-terminal domain of N-methyl-d-aspartate receptor expressed in Escherichia coli.

  2007cited by this paper
• Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides.

  2007cited by this paper
• The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys

  2007cited by this paper
• NMDA receptor subunits: function and pharmacology.

  2007cited by this paper
• Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways

  2007cited by this paper
• Endogenous Alkaline Transients Boost Postsynaptic NMDA Receptor Responses in Hippocampal CA1 Pyramidal Neurons

  2007cited by this paper
• The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

  2007cited by this paper
• Subtype-dependence of N-methyl-D-aspartate receptor modulation by pregnenolone sulfate.

  2006cited by this paper
• Glutamate receptors at atomic resolution

  2006influential reference
• Glutamate-based therapeutic approaches: NR2B receptor antagonists.

  2006cited by this paper
• Developmental Changes in NMDA Neurotoxicity Reflect Developmental Changes in Subunit Composition of NMDA Receptors

  2006cited by this paper
• In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist.

  2006cited by this paper
• Relating NMDA Receptor Function to Receptor Subunit Composition: Limitations of the Pharmacological Approach

  2006influential reference
• An animal model of chronic inflammatory pain: Pharmacological and temporal differentiation from acute models

  2006cited by this paper
• Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia

  2006cited by this paper
• Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites

  2006cited by this paper
• NMDA receptor function: subunit composition versus spatial distribution

  2006cited by this paper
• A double-blind, placebo-controlled study of memantine in the treatment of major depression.

  2006cited by this paper
• NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore.

  2006cited by this paper
• Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.

  2006cited by this paper
• NR2B subtype-selective NMDA receptor antagonists: 2001 – 2004

  2005cited by this paper
• 20-Oxo-5β-Pregnan-3α-yl Sulfate Is a Use-Dependent NMDA Receptor Inhibitor

  2005cited by this paper
• Mismatch negativity in schizophrenia: a meta-analysis.

  2005cited by this paper
• Subunit arrangement and function in NMDA receptors

  2005cited by this paper
• 20-oxo-5beta-pregnan-3alpha-yl sulfate is a use-dependent NMDA receptor inhibitor.

  2005cited by this paper
• Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

  2005cited by this paper
• In vitro characterization of novel NR2B selective NMDA receptor antagonists.

  2005cited by this paper
• Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat

  2005cited by this paper
• Neurosteroids: endogenous regulators of the GABAA receptor

  2005cited by this paper
• Expression and characterization of soluble amino‐terminal domain of NR2B subunit of N‐methyl‐d‐aspartate receptor

  2005influential reference
• Modulation of triheteromeric NMDA receptors by N-terminal domain ligands.

  2005influential reference
• The Micromolar Zinc-Binding Domain on the NMDA Receptor Subunit NR2B

  2005influential reference
• Protons Trap NR1/NR2B NMDA Receptors in a Nonconducting State

  2005cited by this paper
• Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat

  2005cited by this paper
• The function of the amino terminal domain in NMDA receptor modulation.

  2005cited by this paper
• Molecular Mechanism of Pregnenolone Sulfate Action at NR1/NR2B Receptors

  2004cited by this paper
• The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies.

  2004cited by this paper
• Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.

  2004cited by this paper
• NR2B-Containing Receptors Mediate Cross Talk among Hippocampal Synapses

  2004cited by this paper
• A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity.

  2004influential reference
• Role of Distinct NMDA Receptor Subtypes at Central Synapses

  2004cited by this paper
• NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.

  2004cited by this paper
• Amino terminal domain regulation of NMDA receptor function.

  2004influential reference
• Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating.

  2003influential reference
• Identification of Critical Residues in the Amino Terminal Domain of the Human NR2B Subunit Involved in the RO 25-6981 Binding Pocket

  2003cited by this paper
• Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand‐binding core

  2003cited by this paper
• The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze.

  2003cited by this paper
• The Yin and Yang of NMDA receptor signalling.

  2003cited by this paper
• Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists.

  2003cited by this paper
• Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.

  2003cited by this paper
• 2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.

  2003cited by this paper
• Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit

  2003cited by this paper
• Development and Subunit Composition of Synaptic NMDA Receptors in the Amygdala: NR2B Synapses in the Adult Central Amygdala

  2003cited by this paper
• Orally efficacious NR2B-selective NMDA receptor antagonists.

  2003cited by this paper
• 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists.

  2003cited by this paper
• Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids

  2002cited by this paper
• Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.

  2002cited by this paper
• Mapping the Binding Site of the Neuroprotectant Ifenprodil on NMDA Receptors

  2002influential reference
• Pharmacological Characterization of Ro 63-1908 (1-[2-(4-Hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a Novel Subtype-SelectiveN-Methyl-d-Aspartate Antagonist

  2002cited by this paper
• NR2B selective NMDA receptor antagonists.

  2002cited by this paper
• Mechanism of glutamate receptor desensitization

  2002influential reference
• Genetic enhancement of inflammatory pain by forebrain NR2B overexpression

  2001cited by this paper
• NR2B-containing NMDA autoreceptors at synapses on entorhinal cortical neurons.

  2001cited by this paper
• Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial.

  2001cited by this paper
• Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study

  2001cited by this paper
• NMDA receptor antagonists as analgesics: focus on the NR2B subtype.

  2001influential reference
• Exon 5 and spermine regulate deactivation of NMDA receptor subtypes.

  2000cited by this paper
• Antidepressant effects of ketamine in depressed patients.

  2000cited by this paper
• Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators.

  2000cited by this paper
• Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors.

  2000influential reference
• Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomized controlled trial.:

  2000cited by this paper
• Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors.

  2000influential reference
• Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca(2+) accumulation and cell death.

  2000cited by this paper
• Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

  2000cited by this paper
• Geometry and Charge Determine Pharmacological Effects of Steroids on N-Methyl-D-aspartate Receptor-Induced Ca 2 1 Accumulation and Cell Death 1

  2000cited by this paper
• The actions of synaptically released zinc at hippocampal mossy fiber synapses.

  2000cited by this paper
• Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats.

  2000cited by this paper
• Molecular organization of a zinc binding n-terminal modulatory domain in a NMDA receptor subunit.

  2000influential reference
• The glutamate receptor ion channels.

  1999cited by this paper

• meso-2,3-dibromosuccinic acid as a temperature-dependent catalyst for the selective synthesis of syn and anti-highly functionalized tetrahydropyridines: experimental and theoretical study

  2026cites this paper
• Future Perspectives of NMDAR in CNS Disorders

  2025cites this paper
• Optochemical profiling of NMDAR molecular diversity at synaptic and extrasynaptic sites

  2025cites this paper
• Structural insights into GluN2B-containing NMDA receptor antagonists: a computational approach

  2025cites this paper
• Targeting Excitatory Glutamate Receptors for Morphine Tolerance: A Narrative Review

  2025cites this paper
• The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies

  2025cites this paper
• Inhibition of GluN2B-containing N-methyl-d-aspartate receptors by radiprodil.

  2025cites this paper
• Potential benefits of l-serine in children with GRIN2B loss-of-function variants: Randomized n-of-1 trials.

  2025cites this paper
• Precision therapies for genetic epilepsies in 2025: Promises and pitfalls.

  2025cites this paper
• NMDA receptor antagonists mitigate COVID-19-induced neuroinflammation and improve survival in a mouse model

  2025cites this paper
• Ifenprodil inhibits nicotine-induced addiction-like behaviors in mice.

  2025cites this paper
• Accommodating Statistical and Physics-Based Computational Protocols for Molecular Glue Model and Evaluation

  2025cites this paper
• A genetically encoded secreted toxin potentiates synaptic NMDA receptors in hippocampal neurons and confers neuroprotection

  2025cites this paper
• Dual Role of NMDAR Containing NR2A and NR2B Subunits in Alzheimer’s Disease

  2024cites this paper
• Dizocilpine derivatives with neuroprotective effect lacking the psychomimetic side effects

  2024cites this paper
• Reversible Control of Native GluN2B-Containing NMDA Receptors with Visible Light

  2024cites this paper
• Quinolone bioisosteres of phenolic GluN2B‐selective NMDA receptor antagonists

  2024cites this paper
• Selective Enhancement of the Interneuron Network and Gamma-Band Power via GluN2C/GluN2D NMDA Receptor Potentiation

  2024cites this paper
• N-Methyl-D-Aspartate (NMDA) Receptor Antagonists and Their Pharmacological Implication: A Medicinal Chemistry-Oriented Perspective Outline.

  2024cites this paper
• Inhibition of GluN2D-Containing NMDA Receptors Protects Dopaminergic Neurons against 6-OHDA-Induced Neurotoxicity via Activating ERK/NRF2/HO-1 Signaling.

  2024cites this paper
• NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders

  2024cites this paper
• Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder

  2024cites this paper
• Anesthetic Approach in Anti-N-methyl-D-aspartate Receptor Encephalitis Associated with Ovarian Teratoma: A Case Report

  2024cites this paper
• Spinal antinociceptive effect of the PnTx4(5-5) peptide is possibly mediated by the NMDA autoreceptors

  2024cites this paper
• Enantiomerically Pure Indazole Bioisosteres of Ifenprodil and Ro 25-6981 as Negative Allosteric Modulators of NMDA Receptors with the GluN2B Subunit.

  2024cites this paper
• The Analgesic Mechanism of Radix Wikstroemia indica “Sweat Soaking Method” Processed Product Based on Metabolomics and Network Pharmacology

  2024cites this paper
• Acridine yellow G as a photo-induced electron transfer catalyzed radical [4 + 2] aza-Diels-Alder annulation of imines

  2024cites this paper
• Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development

  2024cites this paper
• Glycine Transporter 1 Inhibitors: Predictions on Their Possible Mechanisms in the Development of Opioid Analgesic Tolerance

  2024cites this paper
• Reversible inhibition of GluN2B-containing NMDA receptors with an in situ red-shifted, photoswitchable antagonist

  2023cites this paper
• Indazole as a Phenol Bioisostere: Structure-Affinity Relationships of GluN2B-Selective NMDA Receptor Antagonists.

  2023cites this paper
• Negative allosteric modulators of NMDA receptors with GluN2B subunit: synthesis of β-aminoalcohols by epoxide opening and subsequent rearrangement.

  2023cites this paper
• Research progress and perspectives of N-methyl-D-aspartate receptor in myocardial and cerebral ischemia-reperfusion injury: A review

  2023cites this paper
• Predicting crystal form stability under real-world conditions

  2023cites this paper
• GluN2A and GluN2B N-Methyl-D-Aspartate Receptor (NMDARs) Subunits: Their Roles and Therapeutic Antagonists in Neurological Diseases

  2023cites this paper
• N-methyl-D-aspartate receptor hypofunction as a potential contributor to the progression and manifestation of many neurological disorders

  2023cites this paper
• Development of a Dihydroquinoline–Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the N-Methyl-d-aspartate Receptor

  2023cites this paper
• Some neurotoxic effects of lead nanoparticles on NMDA glutamate receptor gene expression and behavioral responses in Wistar rats

  2023cites this paper
• Identification and in silicon binding study of a novel NR2B selective NMDAR antagonist.

  2023cites this paper
• Characterization of (R)- and (S)-[18F]OF-NB1 in Rodents as Positron Emission Tomography Probes for Imaging GluN2B Subunit-Containing N-Methyl-d-Aspartate Receptors.

  2023cites this paper
• NMDA receptors – regulatory function and pathophysiological significance for pancreatic beta cells

  2023cites this paper
• GluN2B subunit selective N-methyl-D-aspartate receptor ligands: Democratizing recent progress to assist the development of novel neurotherapeutics

  2023cites this paper
• Mechanisms of NMDA receptor regulation.

  2023cites this paper
• GluN2B inhibition confers resilience against long-term cocaine-induced neurocognitive sequelae

  2022cites this paper
• Targeting NMDA Receptors at the Neurovascular Unit: Past and Future Treatments for Central Nervous System Diseases

  2022cites this paper
• Development and Validation of [3H]OF-NB1 for Preclinical Assessment of GluN1/2B Candidate Drugs

  2022cites this paper
• Pharmacological characterization and differential expression of NMDA receptor subunits in the chicken vestibular system during development

  2022cites this paper
• NMDA receptors: Biological properties and their roles in neuropsychiatric disorders

  2022cites this paper
• Tetrahydropyridines’ Stereoselective Formation, How Lockdown Assisted in the Identification of the Features of Its Mechanism

  2022cites this paper
• Protein quality control of N-methyl-D-aspartate receptors

  2022cites this paper
• Negative allosteric modulators of NMDA receptors with GluN2B subunit: Alanine‐derived benzoxazolone bioisosteres of 2‐methyl‐3‐benzazepine‐1,7‐diols

  2022cites this paper
• Phenol‐benzoxazolone bioisosteres of GluN2B‐NMDA receptor antagonists: Unexpected rearrangement during reductive alkylation with phenylcyclohexanone

  2022cites this paper
• Chemical, pharmacodynamic and pharmacokinetic characterization of the GluN2B receptor antagonist 3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-1,7-diol – starting point for PET tracer development

  2022cites this paper
• Synthesis of oxazolo‐annulated 3‐benzazepines designed by merging two negative allosteric NMDA receptor modulators

  2022cites this paper
• Opportunities for Precision Treatment of GRIN2A and GRIN2B Gain-of-Function Variants in Triheteromeric N-Methyl-D-Aspartate Receptors

  2022cites this paper
• The BDNF-TrkB signaling pathway in the rostral anterior cingulate cortex is involved in the development of pain aversion in rats with bone cancer via NR2B and ERK-CREB signaling.

  2022cites this paper
• Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers

  2022cites this paper
• Phenol—Benzoxazolone bioisosteres: Synthesis and biological evaluation of tricyclic GluN2B‐selective N‐methyl‐ d‐aspartate receptor antagonists

  2022cites this paper
• ATTENUATION OF OXIDATIVE STRESS AND NEUROTOXICITY BY MK-801 (DIZOCILPINE) ON DIPENTYLPHTHALATE-INDUCED COGNITIVE DYSFUNCTION IN MICE

  2022cites this paper
• Targeting NMDA Receptor Complex in Management of Epilepsy

  2022cites this paper
• GIRK Channels as Candidate Targets for the Treatment of Substance Use Disorders

  2022cites this paper
• Amyloid-β (25-35) induces the morphological alteration of dendritic spines and decreases NR2B and PSD-95 expression in the hippocampus.

  2022cites this paper
• Ventral hippocampal NMDA receptors mediate the effects of nicotine on stress-induced anxiety/exploratory behaviors in rats.

  2022cites this paper
• Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy

  2021cites this paper
• Photochemical control of drug efficacy - a comparison of uncaging and photoswitching ifenprodil on NMDA receptors.

  2021cites this paper
• Gastrodin Attenuates Tourette Syndrome by Regulating EAATs and NMDA Receptors in the Striatum of Rats

  2021cites this paper
• Inhibition of the ERK1/2 Phosphorylation by Dextromethorphan Protects against Core Autistic Symptoms in VPA Induced Autistic Rats: In Silico and in Vivo Drug Repurposition Study.

  2021cites this paper
• NDT_A_305925 2243..2255

  2021cites this paper
• Enhanced wound healing activity of nano ZnO and nano Curcuma longa in third-degree burn

  2021cites this paper
• Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential

  2021influential citation
• A Conantokin Peptide Con-T[M8Q] Inhibits Morphine Dependence with High Potency and Low Side Effects

  2021cites this paper
• In Vivo Receptor Visualization and Evaluation of Receptor Occupancy with Positron Emission Tomography.

  2021cites this paper
• A GluN2B-selective inhibitor of NMDA receptor function with enhanced potency at acidic pH and oral bioavailability for clinical use

  2021cites this paper
• First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-11C-Me-NB1

  2021cites this paper
• Pathophysiological Ionotropic Glutamate Signalling in Neuroinflammatory Disease as a Therapeutic Target

  2021cites this paper
• Upregulated mGluR5 induces ER stress and DNA damage by regulating the NMDA receptor subunit NR2B.

  2021cites this paper
• Highly diastereoselective four-component synthesis of polysubstituted 1,4,5,6-tetrahydropyridines

  2021cites this paper
• Selective Inhibition of N -Methyl- D -aspartate Receptors with GluN2B Subunit Protects b Cells against Stress-Induced Apoptotic Cell Death S

  2021cites this paper
• A Glutamate N-Methyl-d-Aspartate (NMDA) Receptor Subunit 2B–Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use

  2021cites this paper
• Interactions Between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art.

  2021cites this paper
• GluN2A and GluN2B NMDA receptors use distinct allosteric routes

  2021cites this paper
• Fentanyl-induced hyperalgesia and analgesic tolerance in male rats: common underlying mechanisms and prevention by a polyamine deficient diet

  2021cites this paper
• Decreased Brain pH and Pathophysiology in Schizophrenia

  2021cites this paper
• Heroin exposure and withdrawal differentially influence expression of NMDA receptor NR2 subunits in the prelimbic region of rat medial prefrontal cortex.

  2020cites this paper
• Inhibitory regulation of calcium transients in prefrontal dendritic spines is compromised by a nonsense Shank3 mutation

  2020cites this paper
• Identification of tetracyclic lactams as NMDA receptor antagonists with potential application in neurological disorders.

  2020cites this paper
• Green and Convenient One-Pot Access to Polyfunctionalized Piperidine Scaffolds via Glutamic Acid Catalyzed Knoevenagel- Intramolecular [4+2] aza-Diels-Alder Imin-Based Multi-Component Reaction Under Ambient Temperature

  2020cites this paper
• Sex-Dependent Effects of Developmental Lead Exposure in Wistar Rats: Evidence from Behavioral and Molecular Correlates

  2020cites this paper
• GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer’s Disease Models

  2020cites this paper
• Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice.

  2020cites this paper
• Development of PET and SPECT Radioligands for In Vivo Imaging of NMDA Receptors

  2020cites this paper
• NMDA receptor-dependent long-term depression in the lateral habenula: implications in physiology and depression

  2020cites this paper
• Preclinical Development of 18F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis

  2020cites this paper
• Design, Synthesis and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders.

  2020cites this paper
• A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists.

  2020cites this paper
• Use of a physiologically based pharmacokinetic–pharmacodynamic model for initial dose prediction and escalation during a paediatric clinical trial

  2020cites this paper
• Synthesis and preliminary evaluation of novel 11C-labeled GluN2B-selective NMDA receptor negative allosteric modulators

  2020cites this paper
• Repurposing of cefpodoxime proxetil as potent neuroprotective agent through computational prediction and in vitro validation

  2020cites this paper
• N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)

  2020cites this paper
• Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.

  2019cites this paper